Optic neuritis induced by Pembrolizumab treatment for recurrent vulvar cancer - 29/03/25
, Yonah Levy b, Kristy Ward c
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Purpose |
To describe a novel case of optic neuritis induced after pembrolizumab treatment for recurrent vulvar cancer.
Background |
Immunotherapy is becoming increasingly important as a therapy for cases of vulvar cancer that are resistant to standard treatment.
Case presentation |
A 53-year-old female with a history of recurrent vulvar cancer presented with sudden-onset progressive vision loss in both eyes for four weeks. Initially patient was thought to have brain metastases based on imaging, but after a thorough workup, the diagnosis of optic neuritis was made. Pembrolizumab therapy was immediately ceased, and high-dose corticosteroids were used to treat the patient effectively and reverse her symptoms.
Conclusions |
Several cases of CNS toxicity and optic neuritis have been reported with the use of pembrolizumab immunotherapy but, to our knowledge, this is the first reported case to have occurred in the setting of recurrent vulvar cancer. In these cases it is important to have prompt discontinuation of the offending agent and treatment with high-dose corticosteroid course.
Le texte complet de cet article est disponible en PDF.Keywords : Pembrolizumab, Immunotherapy, Immunotherapy toxicity, Recurrent vulvar cancer, Optic neuritis
Plan
Vol 10
Article 100162- juin 2025 Retour au numéro
Article précédent
- Effects of Sahaj Samadhi Meditation on health-related quality of life of glaucoma patients: A feasibility study
- Monali S. Malvankar-Mehta, Hyunsoo (Jason) Jang, Brian Yu, Cindy Hutnik
- Corneal innervation and neurotisation: A review of current concepts
- Christian P. Pappas
Bienvenue sur EM-consulte, la référence des professionnels de santé.